US-based medical technology company BD has unveiled BD Research Cloud, its new cloud-based software solution intended to streamline the cytometry workflow.
BD Research Cloud is a cloud-based open system built on industry-standard cloud infrastructure and is specially optimised for the company’s instruments and reagents.
It was developed by the same software engineers who created BD’s FlowJo Software and is said to integrate all of the flow cytometry workflow steps.
The future releases of the tool will provide users with more intuitive capabilities, in addition to resources including panel design education, e-books and dedicated app support from BD.
BD Research Cloud enables scientists working across immunology, virology, oncology and infectious disease, to rapidly conduct high-quality experiments, said the company.
BD Biosciences worldwide president Steve Conly said: “BD is committed to delivering innovative solutions to our customers that enhance the quality and efficiency of their flow cytometry research in new and meaningful ways.
“BD Research Cloud is a powerful all-in-one platform that connects instruments, reagents and data analysis, bringing more complex experiments within reach — which can aid and propel potentially life-changing research from discovery to drug development.
“In combination with other BD innovations, including our new BD Horizon RealYellow and RealBlue Reagents and newly unveiled BD FACSDiscover S8 Cell Sorter with BD CellView Image Technology, BD is unlocking new potential for flow cytometry to optimise and advance groundbreaking research.”
According to the company, flow cytometry involves a detailed study and analysis of single cells based on their characteristics to better understand health and disease.
Conventional flow cytometry workflows can be time-consuming, inefficient, and may involve several incompatible systems.
The company said its BD Research Cloud will enable scientists to easily design reagent panels, connect instruments with data analysis software, store experimental data and procedures, and collaborate with colleagues.
Recently, BD and CerTest Biotec have commercially rolled out their new molecular PCR assay for the monkeypox virus for use in the US and global markets.
The new PCR assay, dubbed CerTest VIASURE Monkeypox molecular assay, is offered to laboratories for research use only (RUO) applications.
It has been developed using the BD MAX System open architecture reagent suite.
